Levosimendan Waymade

Active Ingredient:: Levosimendan
Origin:: EU

Levosimendan Waymade (Levosimendan)

Q: What is Levosimendan Waymade used for?

Levosimendan Waymade is an intravenous calcium sensitizer indicated for the treatment of acute decompensated heart failure. It helps improve cardiac contractility and reduces symptoms in patients hospitalized with severe heart failure.

Q: How does Levosimendan work in the body?

Levosimendan binds to troponin C, increasing its sensitivity to calcium and thereby strengthening heart muscle contraction without raising intracellular calcium. It also opens ATP‑sensitive potassium channels in blood vessels, causing vasodilation and lowering both preload and afterload.

Q: What is the usual dose of Levosimendan Waymade?

The dosing regimen for Levosimendan Waymade is determined by the prescribing clinician based on the patient’s clinical condition, weight, and response. Healthcare professionals set the infusion rate and duration according to established guidelines.

Q: Is Levosimendan safe during pregnancy or breastfeeding?

The safety of Levosimendan in pregnancy and lactation has not been established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and decisions are made by the treating physician.

Q: How do I order Levosimendan Waymade from GNH India?

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Q: How does Levosimendan compare with other inotropes?

Unlike traditional catecholamine inotropes, Levosimendan increases contractility by sensitizing troponin C to calcium and provides vasodilation through potassium‑channel activation. This dual action can improve cardiac output with a lower risk of tachyarrhythmias compared with agents that raise intracellular calcium levels.

Q: What are the storage requirements for Levosimendan Waymade?

Levosimendan Waymade should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until ready for use.

Q: How is Levosimendan Waymade administered?

Levosimendan Waymade is given as an intravenous infusion. The initial loading dose is followed by a continuous infusion, administered under close hemodynamic monitoring in a hospital setting.

Q: What are the most serious risks associated with Levosimendan?

Serious risks include severe hypotension, ventricular arrhythmias, myocardial ischemia, and rare allergic reactions such as anaphylaxis. Continuous blood pressure and ECG monitoring are essential during therapy.

Q: Who should not receive Levosimendan Waymade?

Levosimendan is contraindicated in patients with systolic blood pressure below 90 mmHg, severe obstructive cardiomyopathy, or known hypersensitivity to the drug. Caution is advised in recent myocardial infarction, severe renal impairment, and when used with strong CYP3A4 inhibitors.

Levosimendan, the active ingredient in Levosimendan Waymade, is a calcium sensitizer presented as an injectable solution for intravenous use. It is employed in the management of acute decompensated heart failure to improve cardiac contractility and reduce symptoms in hospitalized patients.
GNH India supplies Levosimendan Waymade as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Manufacturer / TM Owner

Waymade B.V.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Levosimendan is used in the acute heart‑failure pathway to support cardiac function in severe decompensation.

Acute decompensated heart failure: enhances myocardial contractility and reduces pulmonary congestion, helping stabilize hemodynamics.

How It Works

Levosimendan increases myocardial contractility by binding to troponin C and sensitizing it to calcium, which enhances the force of contraction without raising intracellular calcium levels. Simultaneously, it opens ATP‑sensitive potassium channels in vascular smooth muscle, causing vasodilation and reducing both preload and afterload, thereby improving overall cardiac output.

Side Effects

Levosimendan may be associated with a range of adverse reactions that clinicians monitor during therapy.

Common Side Effects

Hypotension: drop in blood pressure, especially during infusion.
Headache: mild to moderate intensity.
Nausea: occasional gastrointestinal upset.
Flushing: transient warmth and redness of skin.
Tachycardia: increased heart rate.
Dizziness: related to blood pressure changes.

Serious or Rare Side Effects

Severe hypotension: may require vasopressor support.
Ventricular arrhythmias: potentially life‑threatening rhythm disturbances.
Myocardial ischemia: chest pain or ECG changes.
Allergic reactions: rash, bronchospasm, or anaphylaxis.
Pulmonary edema worsening: rare exacerbation of fluid overload.

Precautions & Warnings

Levosimendan should be administered with careful clinical monitoring to mitigate risks.

Blood pressure monitoring: check systolic pressure before and during infusion.
Cardiac rhythm observation: continuous ECG to detect arrhythmias.
Contraindication in severe hypotension: avoid use when systolic BP <90 mmHg.
Caution in recent myocardial infarction: assess risk of ischemia.
Renal impairment: adjust monitoring as drug metabolites are renally excreted.
Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Avoid Interactions

Levosimendan may interact with other cardiovascular agents, requiring dose adjustments or monitoring.

Major Interactions (Avoid)

Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase plasma levels, risk of toxicity.
Concurrent potent vasodilators (e.g., nitroglycerin, hydralazine): may cause severe hypotension.

Moderate Interactions (Monitor Closely)

Other inotropes (e.g., dobutamine): additive effects on contractility.
Beta‑blockers: may blunt desired increase in heart rate.
Diuretics: enhanced diuresis may affect volume status.
Anticoagulants: monitor for bleeding if hypotension occurs.

Frequently Asked Questions

Levosimendan Waymade is an intravenous calcium sensitizer indicated for the treatment of acute decompensated heart failure. It helps improve cardiac contractility and reduces symptoms in patients hospitalized with severe heart failure.

Levosimendan binds to troponin C, increasing its sensitivity to calcium and thereby strengthening heart muscle contraction without raising intracellular calcium. It also opens ATP‑sensitive potassium channels in blood vessels, causing vasodilation and lowering both preload and afterload.

The dosing regimen for Levosimendan Waymade is determined by the prescribing clinician based on the patient’s clinical condition, weight, and response. Healthcare professionals set the infusion rate and duration according to established guidelines.

The safety of Levosimendan in pregnancy and lactation has not been established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and decisions are made by the treating physician.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Unlike traditional catecholamine inotropes, Levosimendan increases contractility by sensitizing troponin C to calcium and provides vasodilation through potassium‑channel activation. This dual action can improve cardiac output with a lower risk of tachyarrhythmias compared with agents that raise intracellular calcium levels.

Levosimendan Waymade should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until ready for use.

Levosimendan Waymade is given as an intravenous infusion. The initial loading dose is followed by a continuous infusion, administered under close hemodynamic monitoring in a hospital setting.

Serious risks include severe hypotension, ventricular arrhythmias, myocardial ischemia, and rare allergic reactions such as anaphylaxis. Continuous blood pressure and ECG monitoring are essential during therapy.

Levosimendan is contraindicated in patients with systolic blood pressure below 90 mmHg, severe obstructive cardiomyopathy, or known hypersensitivity to the drug. Caution is advised in recent myocardial infarction, severe renal impairment, and when used with strong CYP3A4 inhibitors.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 28 Aug 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.